Abstract：
Urothelial Carcinoma (UC) is the most common tumour of the canine urinary bladder. Recently, BRAF mutation testing emerged as a diagnostic option, but its prognostic significance is unknown. This study investigates the relationship between BRAF (variant V595E) mutation status and overall survival in UC-bearing dogs. Seventy-nine patients histologically diagnosed with UC of the bladder and/or urethra between 2006 and 2019 were included in this retrospective single-center-study. Treatment consisted of meloxicam (n=39, group 1 \"Melox\"), mitoxantrone and meloxicam (+/- followed by metronomic chlorambucil) (n=23, group 2 \"Chemo\") or partial cystectomy followed by meloxicam +/- mitoxantrone (n=17, group 3 \"Sx\"). Survival was significantly influenced by treatment (p=0.0002) and tumour location (p<0.001) in both uni- and multivariable analyses. BRAF mutation was identified in 51 tumours (=64.6%) and had no statistically significant influence on overall survival: MST for BRAF-negative patients 359 vs. 214 days for BRAF-positive dogs (p=0.055). However, in BRAF-positive dogs, survival depended significantly on type of treatment in univariable analysis: MSTs for groups 1-3 were 151 days, 244 days, and 853 days, respectively (p=0.006); In BRAF-positive group 2 (\"Chemo\")-patients, adjuvant metronomic chlorambucil after mitoxantrone more than doubled MST compared to patients receiving mitoxantrone alone (588 days vs. 216 days; p=0.030). In contrast, MSTs were not significantly different in BRAF-negative patients among the 3 treatment groups (p=0.069). Multivariate analysis of these data was not possible due to group size limitations. This study identified tumour location and treatment type, but not BRAF mutation status, as independent prognostic factors for overall survival. This article is protected by copyright. All rights reserved.
摘要：
尿路上皮癌（UC）是犬膀胱最常见的肿瘤。最近,BRAF突变检测作为一种诊断选择出现，但其预后意义尚不清楚。这项研究调查了BRAF（变体V595E）突变状态与UC患者总体生存率之间的关系。这项回顾性单中心研究包括了在2006年至2019年之间经组织学诊断为膀胱和/或尿道UC的79例患者。治疗包括美洛昔康（n=39，第1组“Melox”），米托蒽醌和美洛昔康(+/-然后是节律性苯丁酸氮芥)(n=23，第2组“化疗”)或膀胱部分切除术，然后是美洛昔康+/-米托蒽醌(n=17，第3组“Sx”)。在单变量和多变量分析中，生存率受到治疗（p=0.0002）和肿瘤位置（p<0.001）的显着影响。在51例肿瘤中发现BRAF突变（=64.6％），对总体生存率无统计学意义：BRAF阴性患者的MST359例与对于BRAF阳性狗为214天(p=0.055)。然而,在BRAF阳性的狗中，在单变量分析中，生存显著取决于治疗类型：1-3组的MST为151天，244天,853天,分别(p=0.006)；在BRAF阳性2组(“化疗”)患者中，与单独接受米托蒽醌的患者相比，米托蒽醌后的辅助节拍苯丁酸氮芥MST增加了一倍以上（588天与216天；p=0.030）。相比之下,在3个治疗组中，BRAF阴性患者的MSTs没有显着差异（p=0.069）。由于组规模的限制，无法对这些数据进行多变量分析。这项研究确定了肿瘤的位置和治疗类型，但不是BRAF突变状态,作为总生存期的独立预后因素。本文受版权保护。保留所有权利。
